Of course, with further budget cuts expected for the healthcare industry in
2012, cost and patient compliance are two additional factors promoting the use
of DEBs. Offering improved efficacy and patient safety for some indications,
these products have the potential to create a niche market. In fact,
preliminary clinical trial results suggest that DEBs could become the standard
treatment for PVD and complex lesions in the future.
GlobalData analysts suggest that PVD, Small Vessel Disease (SVD), bifurcated lesions
and In-Stent Restenosis (ISR) could represent a $2 billion untapped market.
This market is set to be further boosted by the complications associated with
long-term antiplatelet therapy. The risks of bleeding and contraindications
limit current interventions and further the potential of DEBs in the healthcare
industry.
Among the products set to contribute to the growth of the DEB market is B.
Braun's product, SeQuent Please, which currently accounts for the highest
number of completed and ongoing clinical trials. Bayer's PACCOCATH technology
has also demonstrated success in animal models and both these products are
expected to receive regulatory approval in the next two to three years.
(Source - GLOBALDATA,
Londn, UK)
Source: Medindia